Hoffman Alexander F, Riegel Arthur C, Lupica Carl R
Cellular Neurobiology Research Branch, National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA.
Eur J Neurosci. 2003 Aug;18(3):524-34. doi: 10.1046/j.1460-9568.2003.02773.x.
The possible localization of cannabinoid (CB) receptors to glutamatergic and GABAergic synaptic terminals impinging upon GABAergic interneurons in the CA1 region of the rat hippocampus was examined using the electrophysiological measurement of neurotransmitter release in brain slices. Whereas activation of cannabinoid receptors via the application of the cannabinoid agonist WIN55,212-2 significantly and dose-dependently reduced evoked IPSCs recorded from interneurons possessing somata located in the stratum radiatum (S.R.) and stratum oriens (S.O.) lamellae, evoked glutamatergic EPSCs were unaffected in both neuronal populations. However, in agreement with previous reports, WIN55,212-2 significantly reduced EPSCs recorded from CA1 pyramidal neurons. Additional experiments confirmed that the effects of WIN55,212-2 on IPSCs were presynaptic and that they could be blocked by the CB1 receptor antagonist SR141716A. The involvement of endogenous cannabinoids in the presynaptic inhibition of GABA release was also examined in the interneurons and pyramidal cells using a depolarization-induced suppression of inhibition (DSI) paradigm. DSI was observed in CA1 pyramidal neurons under control conditions, and its incidence was greatly increased by the cholinergic agonist carbachol. However, DSI was not observed in the S.R. or S.O. interneuron populations, in either the presence or absence of carbachol. Whereas DSI was not present in these interneurons, the inhibitory inputs to these cells were modulated by the synthetic cannabinoid WIN55,212-2. These data support the hypothesis that cannabinoid receptors are located on inhibitory, but not excitatory, axon terminals impinging upon hippocampal interneurons, and that CA1 pyramidal neurons, and not interneurons, are capable of generating endogenous cannabinoids during prolonged states of depolarization.
利用脑片神经递质释放的电生理测量方法,研究了大麻素(CB)受体在大鼠海马CA1区作用于γ-氨基丁酸(GABA)能中间神经元的谷氨酸能和GABA能突触终末上的可能定位。通过应用大麻素激动剂WIN55,212-2激活大麻素受体,可显著且剂量依赖性地减少从位于辐射层(S.R.)和原层(S.O.)板层的中间神经元记录到的诱发抑制性突触后电流(IPSCs),而在这两种神经元群体中,诱发的谷氨酸能兴奋性突触后电流(EPSCs)未受影响。然而,与先前报道一致,WIN55,212-2显著减少了从CA1锥体神经元记录到的EPSCs。额外的实验证实,WIN55,212-2对IPSCs的作用是突触前的,且可被CB1受体拮抗剂SR141716A阻断。还利用去极化诱导的抑制抑制(DSI)范式,在中间神经元和锥体细胞中研究了内源性大麻素在GABA释放的突触前抑制中的作用。在对照条件下,在CA1锥体神经元中观察到了DSI,胆碱能激动剂卡巴胆碱可使其发生率大大增加。然而,在S.R.或S.O.中间神经元群体中,无论有无卡巴胆碱,均未观察到DSI。虽然这些中间神经元中不存在DSI,但这些细胞的抑制性输入受到合成大麻素WIN55,212-2的调节。这些数据支持以下假设:大麻素受体位于作用于海马中间神经元的抑制性而非兴奋性轴突终末上,并且在长时间去极化状态下,CA1锥体神经元而非中间神经元能够产生内源性大麻素。